Introduction
This model contains historical and forecast sales data for Mitsubishi Tanabe in the prescription pharmaceutical sector, based on company-reported, IMS and analyst consensus data. The model also presents the company’s R&D pipeline, historical financial data and product profiles.
Reasons to Purchase
- Access key forecast product sales for Mitsubishi Tanabe
- View the company’s financial statements and pipeline data
Other selected research from the 'PharmaVitae' category:
Serono: PharmaVitae Profile
This analysis examines the historical and forecast performance for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Learn More
Bayer Schering Pharma AG: PharmaVitae Profile 2009
This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information Learn More
Other selected research from the 'Companies' category:
Financial Markets Research: Spectrum Pharmaceuticals’ Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market
There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum’s satraplatin, which could offer key advantages due to its oral administration profile. Learn More
Chugai Pharmaceutical Co. Ltd: PharmaVitae Model 2009
This model contains historical and forecast sales data for Chugai in the prescription pharmaceutical sector, based on company-reported, IMS and analyst consensus data. Learn More